Valuation: Becton, Dickinson and Company

Market Cap 42.2B 37B 34.38B 31.57B 59.44B 4,075B 60.4B 409B 160B 1,991B 158B 155B 6,884B P/E 2026 *
38.2x
P/E 2027 * 29.5x
Enterprise Value 58.72B 51.48B 47.83B 43.92B 82.7B 5,669B 84.03B 569B 223B 2,771B 220B 216B 9,578B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 2.85x
Free-Float
74.04%
Yield 2026 *
2.51%
Yield 2027 * 2.56%
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-2.23% - - 42.39B
+0.90%+13.05%-19.17%-12.00% 174B
-0.56%+3.27%-8.71%-7.95% 105B
-0.82%-0.56%+2.70%+56.07% 58.97B
-1.59%-2.05%+36.71%+59.47% 52.24B
-4.89%-3.83% - - 33.05B
-4.44%-3.63%-14.99%-45.31% 28.84B
-0.23%+0.21%+70.61%-5.01% 25.38B
-0.56%+0.88%-5.43%-9.27% 20.64B
-1.85%-1.52%-9.08%+0.50% 20.28B
Average -1.18%+2.21%+6.58%+4.56% 57.6B
Weighted average by Cap. -0.42%+5.01%-2.28%+3.87%

Financials

2026 *2027 *
Net sales 19.21B 16.84B 15.65B 14.37B 27.06B 1,855B 27.5B 186B 72.81B 907B 72.11B 70.57B 3,134B 19.73B 17.29B 16.07B 14.76B 27.78B 1,905B 28.23B 191B 74.75B 931B 74.03B 72.45B 3,218B
Net income 1.12B 986M 916M 841M 1.58B 109B 1.61B 10.9B 4.26B 53.07B 4.22B 4.13B 183B 1.45B 1.27B 1.18B 1.08B 2.04B 140B 2.07B 14.04B 5.49B 68.39B 5.44B 5.32B 236B
Net Debt 16.51B 14.48B 13.45B 12.35B 23.26B 1,595B 23.63B 160B 62.58B 779B 61.98B 60.65B 2,694B 13.96B 12.24B 11.37B 10.44B 19.66B 1,348B 19.98B 135B 52.9B 659B 52.39B 51.27B 2,277B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Trader
Investor
Global
Quality
ESG MSCI
-